Cagrilintide
Sources
registry, as of 2026-10-07Stale
https://clinicaltrials.gov/study/NCT07220759
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 330. Conditions Overweight; Obesity; Type 2 Diabetes. This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Whic
ClinicalTrials.gov NCT07220759 protocol and results modules
registry, as of 2026-08-06Stale
https://clinicaltrials.gov/study/NCT07220642
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 300. Conditions Obesity; Overweight. This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment partici
ClinicalTrials.gov NCT07220642 protocol and results modules
registry, as of 2026-08-25Stale
https://clinicaltrials.gov/study/NCT06719011
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 178. Conditions Obesity; Overweight. This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine N
ClinicalTrials.gov NCT06719011 protocol and results modules
registry, as of 2026-05-15Stale
https://clinicaltrials.gov/study/NCT07557953
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 120. Conditions Overweight; Obesity. The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity. Participants will receive either cagrilintide or placebo, and which treatment participants get is decided by chance. Cagrilintide is th
ClinicalTrials.gov NCT07557953 protocol and results modules
registry, as of 2026-10-19Stale
https://clinicaltrials.gov/study/NCT07607587
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 114. Conditions Obesity; Overweight. The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (t
ClinicalTrials.gov NCT07607587 protocol and results modules
registry, as of 2024-11-01Stale
https://clinicaltrials.gov/study/NCT05804162
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 107. Conditions Obesity. The study tests if treatment with cagrilintide delays the transmission of electrical signals in the heart compared to treatment with placebo. To confirm the sensitivity of the methodology, the drug moxifloxacin is also compared to a placebo in 2 treatment arms. Cagrilintide is be
ClinicalTrials.gov NCT05804162 protocol and results modules
registry, as of 2026-04-13Stale
https://clinicaltrials.gov/study/NCT07411560
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 100. Conditions Overweight; Obese. This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone. In one period participants will get two medicines: cagrilintide and NNC0480-0389. In the other
ClinicalTrials.gov NCT07411560 protocol and results modules
registry, as of 2026-09-04Stale
https://clinicaltrials.gov/study/NCT07605052
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 50. Conditions Overweight; Obesity. The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance.
ClinicalTrials.gov NCT07605052 protocol and results modules
publication, as of 2026-08-18Stale
https://pubmed.ncbi.nlm.nih.gov/42608559/
trials. To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals. A systema
PMID 42608559